{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:47:00Z","timestamp":1790729220590,"version":"4.1.0"},"reference-count":62,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie Corporation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Treatment for acute myeloid leukemia (AML) typically involves intensive chemotherapy (IC); however, there is an unmet need for approximately 50% of AML patients who are deemed unfit or ineligible for IC. The purpose of this study was to evaluate, from a Canadian perspective, the economic impact of venetoclax in combination with azacitidine (Ven+Aza) for the treatment of patients with newly diagnosed AML who are 75 years or older or who have comorbidities that preclude using IC. A lifetime partitioned survival model was developed to assess the cost-effectiveness of Ven+Aza compared with Aza. Health states included event-free survival, progressive\/relapsed disease, and death. Efficacy parameters were based on the VIALE-A trial. Analyses were conducted from Ministry of Health (MoH) and societal perspectives. Over a lifetime horizon, Ven+Aza was associated with a gain of 1.65 quality-adjusted life years (QALYs) compared with Aza. From an MoH perspective, Ven+Aza and Aza were associated with total costs of $204,305 and $82,333, respectively, resulting in an incremental cost\u2013utility ratio of $73,841\/QALY. Results were similar from a societal perspective. This economic evaluation demonstrates that, in comparison with Aza, Ven+Aza is a cost-effective strategy for the treatment of patients with newly diagnosed AML who are deemed unfit for IC.<\/jats:p>","DOI":"10.3390\/curroncol29100592","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T20:43:21Z","timestamp":1665261801000},"page":"7524-7536","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost\u2013Utility Analysis"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5245-1178","authenticated-orcid":false,"given":"Kimberly","family":"Guinan","sequence":"first","affiliation":[{"name":"PeriPharm Inc., Montr\u00e9al, QC H2Y 2H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Mathurin","sequence":"additional","affiliation":[{"name":"PeriPharm Inc., Montr\u00e9al, QC H2Y 2H4, Canada"},{"name":"Faculty of Pharmacy, University de Montreal, Montreal, QC H3T 1J4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunghan","family":"Au","sequence":"additional","affiliation":[{"name":"AbbVie Corporation, Saint Laurent, QC H4S 1Z1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[{"name":"Cancer Clinical Research Unit, Princess Margaret Cancer Center, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cat N.","family":"Bui","sequence":"additional","affiliation":[{"name":"AbbVie Corporation, North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglei","family":"Chai","sequence":"additional","affiliation":[{"name":"Analysis Group Inc., Boston, MA 02199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Lachaine","sequence":"additional","affiliation":[{"name":"PeriPharm Inc., Montr\u00e9al, QC H2Y 2H4, Canada"},{"name":"Faculty of Pharmacy, University de Montreal, Montreal, QC H3T 1J4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/cncr.24373","article-title":"Outcomes and quality of care in acute myeloid leukemia over 40 years","volume":"115","author":"Alibhai","year":"2009","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: Epidemiology and etiology","volume":"107","author":"Deschler","year":"2006","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","unstructured":"GLOBOCAN (2020, October 19). Cancer Today. Available online: http:\/\/gco.iarc.fr\/today\/home."},{"key":"ref_5","unstructured":"Canadian Cancer Society (2020, October 26). Acute Myelogenous Leukemia Statistics. Available online: https:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/leukemia-acute-myelogenous-aml\/statistics\/?region=on."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/s41375-018-0068-2","article-title":"Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: An analysis of Alliance studies","volume":"32","author":"Eisfeld","year":"2018","journal-title":"Leukemia"},{"key":"ref_7","first-page":"1","article-title":"The incidence of acute myeloid leukemia in Calgary, Alberta, Canada: A retrospective cohort study","volume":"18","author":"Shysh","year":"2017","journal-title":"BMC Public Heal."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ctrv.2018.07.005","article-title":"Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia","volume":"69","author":"Bosshard","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1182\/blood.V120.21.3614.3614","article-title":"Overall Economic Burden of Total Treatment Costs in Acute Myeloid Leukemia throughout the Course of the Disease","volume":"120","author":"Mahmoud","year":"2012","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups with Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study","volume":"89","author":"Leith","year":"1997","journal-title":"Blood"},{"key":"ref_13","unstructured":"Tallman, M.S., Altman, J.K., Appelbaum, F.R., Bhatt, V.R., Bixby, D., de Lima, M., Fathi, A.T., Fiorella, M., Foran, J.M., and Gojo, I. (2020). NCCN Clinical Practice Guidelines in Oncology (NCCN): Acute Myeloid Leukemia Version 3.2020, National Comprehensive Cancer Network."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients with Acute Myeloid Leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_15","first-page":"1513","article-title":"Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches","volume":"91","author":"Deschler","year":"2006","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"106339","DOI":"10.1016\/j.leukres.2020.106339","article-title":"Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia","volume":"91","author":"Griffiths","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0774-x","article-title":"Recent drug approvals for acute myeloid leukemia","volume":"12","author":"Lai","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_18","unstructured":"Celgene Inc (2020, October 26). Product Monograph: VIDAZA\u00ae (Azacitidine for Injection). Available online: https:\/\/media.celgene.com\/content\/uploads\/sites\/23\/Vidaza-Product_Monograph_-_English_Version.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/2278-330X.149918","article-title":"Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience","volume":"4","author":"Bashir","year":"2015","journal-title":"S. Asian J. Cancer"},{"key":"ref_20","first-page":"56","article-title":"Treatment of Leukemia with Low Dose Ara-C: A Study of 159 Cases","volume":"29","author":"Castaigne","year":"1985","journal-title":"Haematol. Blood Transfus."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Palmieri, R., Paterno, G., De Bellis, E., Mercante, L., Buzzatti, E., Esposito, F., Del Principe, M.I., Maurillo, L., Buccisano, F., and Venditti, A. (2020). Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness. Cancers, 12.","DOI":"10.3390\/cancers12010120"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/leu.2014.216","article-title":"Management of older or unfit patients with acute myeloid leukemia","volume":"29","author":"Walter","year":"2014","journal-title":"Leukemia"},{"key":"ref_23","first-page":"30","article-title":"Treatment of older patients with acute myeloid leukemia (AML): Revised Canadian consensus guidelines","volume":"7","author":"Brandwein","year":"2017","journal-title":"Am. J. Blood Res."},{"key":"ref_24","unstructured":"(2020, November 02). The Leukemia\/Bone Marrow Transplant Program of BC. Healthcare Professionals Cancer Management Guidelines: Acute Myeloid Leukemia (AML). Available online: http:\/\/www.leukemiabmtprogram.com\/healthcare_professionals\/cancer_management_guidelines\/AML.html."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Pollyea, D.A., Pratz, K.W., Jonas, B.A., Letai, A., Pullarkat, V.A., Wei, A., Konopleva, M.Y., Recher, C., Frankfurt, O., and David Rizzieri, D. (2018, January 1\u20134). Venetoclax in combination with hypomethylating agents induces rapid, deep, and durable responses in patients with AML ineligible for intensive therapy. Proceedings of the American Society of Hematology (ASH)\u201360th Annual Meeting, San Diego, CA, USA.","DOI":"10.1182\/blood-2018-99-117179"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"Dinardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"Dinardo","year":"2018","journal-title":"Blood"},{"key":"ref_28","unstructured":"National Comprehensive Cancer Network (2021). Acute Myeloid Leukemia (Version 3.2021), National Comprehensive Cancer Network."},{"key":"ref_29","unstructured":"National Institute for Health and Care Excellence (NICE) (2020, November 05). Technical Support Document 14. Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient-Level Data. Available online: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12962-018-0153-4","article-title":"Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom","volume":"16","author":"Tremblay","year":"2018","journal-title":"Cost Eff. Resour. Alloc."},{"key":"ref_31","unstructured":"Statistics Canada (2020, November 09). Deaths and Mortality Rates, by Age Group (Table: 13-10-0710-01). Available online: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/cv.action?pid=1310071001."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MLR.0000000000000447","article-title":"A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada","volume":"54","author":"Xie","year":"2016","journal-title":"Med. Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"ref_34","unstructured":"Wehler, E., Storm, M., Kowal, S., Campbell, C., and Boscoe, A. (2018, January 14\u201317). A health state utility model estimating the impact of ivosidenib on quality of life in patients with relapsed\/refractory acute myeloid leukemia. Proceedings of the 23rd Congress of the European Hematology Association, Stockholm, Sweden. Available online: https:\/\/investor.agios.com\/static-files\/25de7161-9a10-4d8c-8a03-8bd5e7d0a5d3."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/JCO.2006.07.0409","article-title":"Cost-Effectiveness Analysis of Computerized Tomography in the Routine Follow-Up of Patients After Primary Treatment for Hodgkin\u2019s Disease","volume":"24","author":"Guadagnolo","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_36","unstructured":"Pratz, K.W., Panayiotidis, P., Recher, C., Wei, X., Jonas, B.A., Montesinos, P., Ivanov, V., Schuh, A.C., Dinardo, C.D., and Novak, J. (2020, January 5\u20138). 589 Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. Proceedings of the 62nd ASH Annual Meeting and Exposition (Virtual), San Diego, CA, USA."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.jval.2021.11.1124","article-title":"POSB357 Health State Utilities for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy","volume":"25","author":"Pratz","year":"2022","journal-title":"Value Health"},{"key":"ref_38","unstructured":"Statistics Canada (2020, October 01). Consumer Price Index by product group, monthly, percentage change, not seasonally adjusted, Canada, provinces, Whitehorse, Yellowknife and Iqaluit (Table: 18-10-0004-13). Available online: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1810000413."},{"key":"ref_39","unstructured":"IQVIA (2020). Delta PA, IQVIA."},{"key":"ref_40","unstructured":"Government of Canada (2020, October 01). Dispensing Fee Policies in Public Drug Plans, 2017\/18. Available online: http:\/\/www.pmprb-cepmb.gc.ca\/view.asp?ccid=1308&lang=en."},{"key":"ref_41","unstructured":"Ministry of Health and Long Term Care of Ontario (2020, October 01). Schedule of Benefits: Physician Services Under the Health Insurance Act (Effective April 1, 2020), Available online: http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/physserv\/sob_master20200306.pdf."},{"key":"ref_42","unstructured":"Cancer Care Ontario (2020, October 01). Drug Formulary-Regimens. Available online: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens?f%5B0%5D=field_type_of_cancer%3A626."},{"key":"ref_43","unstructured":"Government of Canada (2020, October 01). Job Bank-Wage Report. Available online: https:\/\/www.jobbank.gc.ca\/wagereport\/location\/geo9219."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3111\/13696998.2015.1105230","article-title":"Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada","volume":"19","author":"Pettigrew","year":"2015","journal-title":"J. Med. Econ."},{"key":"ref_45","unstructured":"Cancer Care Ontario (2020, November 01). HYDR Regimen. Available online: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens\/monograph\/51466."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: Outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv."},{"key":"ref_47","unstructured":"Ontario Ministry of Health and Long Term Care (2020, October 01). Ontario Care Costing Analysis Tool. Available online: https:\/\/hsimi.ca\/occp\/occpreports\/."},{"key":"ref_48","unstructured":"Interprovincial Health Insurance Agreements Coordinating Committee (IHIACC) (2020, October 01). Interprovincial Billing Rates for Designated High Cost Transplants Effective for Discharges on or after April 1, 2020, Available online: http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/bulletins\/na_86\/high_cost.pdf."},{"key":"ref_49","unstructured":"Canadian Institute for Health Information (2020, October 01). Patient Cost Estimator. Available online: https:\/\/www.cihi.ca\/en\/patient-cost-estimator."},{"key":"ref_50","unstructured":"Canadian Institute for Health Information (2020, October 01). Care in Canadian ICUs. Available online: https:\/\/secure.cihi.ca\/free_products\/ICU_Report_EN.pdf."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/voxs.12355","article-title":"The cost of transfusing a unit of red blood cells: A costing model for Canadian hospital use","volume":"12","author":"Lagerquist","year":"2017","journal-title":"ISBT Sci. Ser."},{"key":"ref_52","unstructured":"Ministry of Health and Long Term Care of Ontario (2020, October 01). Schedule of Benefits of Laboratory Services (Effective July 1, 2020), Available online: http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/lab\/lab_mn2020.pdf."},{"key":"ref_53","unstructured":"Canadian Cancer Society (2020, October 01). Follow-Up After Treatment for Acute Myelogenous Leukemia. Available online: https:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/leukemia-acute-myelogenous-aml\/treatment\/follow-up\/?region=on."},{"key":"ref_54","first-page":"1","article-title":"Phase-specific and lifetime costs of cancer care in Ontario, Canada","volume":"809","author":"Pataky","year":"2016","journal-title":"BMC Cancer"},{"key":"ref_55","unstructured":"Statistics Canada (2020, October 01). Average Usual Hours and Wages by Selected Characteristics, Monthly, Unadjusted for Seasonality (Table: 14-10-0320-02). Available online: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1410032002."},{"key":"ref_56","unstructured":"Statistics Canada (2020, October 01). Labour Force Characteristics by Age Group, Monthly, Seasonally Adjusted (Table: 14-10-0287-02). Available online: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/cv.action?pid=1410028702."},{"key":"ref_57","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) (2020, October 01). Guidelines for the Economic Evaluation of Health Technologies: Canada, 4th Edition. Available online: https:\/\/www.cadth.ca\/guidelines-economic-evaluation-health-technologies-canada-4th-edition."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood-2021-148338","article-title":"Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective","volume":"138","author":"Pratz","year":"2021","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/bloodadvances.2020003902","article-title":"Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv."},{"key":"ref_60","unstructured":"Cancer Care Ontario (2020, November 25). AZCTVENE Regimen. Available online: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens\/monograph\/66881."},{"key":"ref_61","unstructured":"Cancer Care Ontario (2020, November 01). CYTA(LD) Regimen. Available online: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens\/monograph\/51351."},{"key":"ref_62","unstructured":"American Cancer Society (2020, October 01). Stem Cell Transplant for Acute Myeloid Leukemia (AML). Available online: https:\/\/www.cancer.org\/cancer\/acute-myeloid-leukemia\/treating\/bone-marrow-stem-cell-transplant.html."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/10\/592\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:48:02Z","timestamp":1760143682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/10\/592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":62,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["curroncol29100592"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29100592","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]}}}